| scholarly article | Q13442814 |
| P50 | author | Srinivasan Yegnasubramanian | Q95939090 |
| P2093 | author name string | Richard J Jones | |
| William G Nelson | |||
| Michael C Haffner | |||
| Jessica L Gucwa | |||
| Jonathan M Gerber | |||
| Milada Vala | |||
| David Esopi | |||
| Meltem Gurel | |||
| P2860 | cites work | Gene ontology: tool for the unification of biology | Q23781406 |
| BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. | Q51141709 | ||
| Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. | Q54581100 | ||
| TGF-beta1-induced PI3K/Akt/NF-kappaB/MMP9 signalling pathway is activated in Philadelphia chromosome-positive chronic myeloid leukaemia hemangioblasts. | Q54615784 | ||
| Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation | Q61872970 | ||
| Characterization of CD3 4+HLA-DR−CD38+and CD34+HLA-DR−CD38−progenitor cells from human umbilical cord blood | Q71642218 | ||
| Improved purification of hematopoietic stem cells based on their elevated aldehyde dehydrogenase activity | Q80709761 | ||
| The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence | Q83214926 | ||
| KEGG: kyoto encyclopedia of genes and genomes | Q24515297 | ||
| Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 | ||
| Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources | Q27860739 | ||
| Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists | Q28131785 | ||
| KEGG for integration and interpretation of large-scale molecular data sets | Q29547277 | ||
| Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 | ||
| In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment | Q30484167 | ||
| Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells | Q33526746 | ||
| Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein | Q34136730 | ||
| Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer | Q34295041 | ||
| Characterization of chronic myeloid leukemia stem cells. | Q34443802 | ||
| Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). | Q35034758 | ||
| The two faces of transforming growth factor beta in carcinogenesis | Q35170231 | ||
| Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) | Q35694453 | ||
| Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. | Q35828024 | ||
| Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease | Q35876184 | ||
| A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia | Q35885317 | ||
| Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia | Q36047171 | ||
| Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. | Q36163066 | ||
| Normal and leukaemic stem cells | Q36228053 | ||
| Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer | Q36516410 | ||
| DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases | Q36623924 | ||
| Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases | Q36816872 | ||
| DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. | Q36992241 | ||
| Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. | Q37400834 | ||
| Pushing the limits of targeted therapy in chronic myeloid leukaemia. | Q38028778 | ||
| TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia | Q39744014 | ||
| Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia | Q40161241 | ||
| Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors | Q40393545 | ||
| MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models | Q40667580 | ||
| Quantitative assessment of gene expression in highly purified hematopoietic cells using real-time reverse transcriptase polymerase chain reaction | Q40729723 | ||
| Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer | Q42723815 | ||
| Gene set enrichment analysis made simple | Q42795507 | ||
| Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial | Q42851077 | ||
| Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro | Q43833442 | ||
| Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment | Q44308354 | ||
| Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes. | Q44389000 | ||
| High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia | Q44834786 | ||
| Discontinuation of imatinib therapy after achieving a molecular response | Q45065538 | ||
| Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction | Q46937459 | ||
| Anti-CD25 immunotherapy: regulating the regulators | Q48634042 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic myeloid leukemia | Q729735 |
| P304 | page(s) | 715-728 | |
| P577 | publication date | 2013-05-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations | |
| P478 | volume | 4 |
| Q33820371 | A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients |
| Q34170309 | A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. |
| Q37705779 | Abnormal expression of TGF-beta type II receptor isoforms contributes to acute myeloid leukemia |
| Q39170884 | Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments. |
| Q37216232 | Association of acute myeloid leukemia's most immature phenotype with risk groups and outcomes |
| Q90706502 | BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia |
| Q36678835 | BMP and Hedgehog Regulate Distinct AGM Hematopoietic Stem Cells Ex Vivo |
| Q52735344 | CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting. |
| Q38803617 | CD90 a potential cancer stem cell marker and a therapeutic target |
| Q92380918 | CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy |
| Q59798121 | Cancer Stem Cells: Emergent Nature of Tumor Emergency |
| Q40075528 | Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia. |
| Q58751747 | Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal |
| Q33781150 | Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein |
| Q35801149 | Clinical and Genetic Factors Associated with Cutaneous Squamous Cell Carcinoma in Kidney and Heart Transplant Recipients |
| Q38265115 | DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia |
| Q26991974 | Deconstructing innate immune signaling in myelodysplastic syndromes |
| Q34334463 | Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis |
| Q54978822 | Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients. |
| Q35075436 | Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell response |
| Q62057736 | Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia |
| Q39109931 | EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression |
| Q38812117 | Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications. |
| Q36524988 | GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress |
| Q34781322 | Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia |
| Q47136924 | Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinib. |
| Q36765731 | High expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-acute lymphoblastic leukemia |
| Q88721028 | IL1RAP potentiates multiple oncogenic signaling pathways in AML |
| Q36755221 | Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. |
| Q93017003 | Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML |
| Q35650523 | Leukemia stem cells: the root of chronic myeloid leukemia |
| Q38252432 | New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia |
| Q99572773 | Prognostic Value of SLC4A4 and its Correlation with Immune Infiltration in Colon Adenocarcinoma |
| Q37719006 | Regulation and roles of bicarbonate transporters in cancer |
| Q37218410 | Regulation of human hematopoietic stem cell self-renewal by the microenvironment's control of retinoic acid signaling |
| Q47916938 | Research of differential expression of sIL1RAP in low-grade gliomas between children and adults. |
| Q52719191 | Screening potential biomarkers for colorectal cancer based on circular RNA chips. |
| Q48144472 | Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia |
| Q38170621 | Stem cell-directed therapies in pancreatic cancer |
| Q26745531 | The Philadelphia chromosome in leukemogenesis |
| Q54982375 | The c-Raf modulator RRD-251 enhances nuclear c-Raf/GSK-3/VDR axis signaling and augments 1,25-dihydroxyvitamin D3-induced differentiation of HL-60 myeloblastic leukemia cells. |
| Q89453423 | The quiescent fraction of chronic myeloid leukemic stem cells depends on BMPR1B, Stat3 and BMP4-niche signals to persist in patients in remission |
| Q38238611 | The role of the bone morphogenetic proteins in leukaemic stem cell persistence. |
| Q30244186 | Translating leukemia stem cells into the clinical setting: Harmonizing the heterogeneity |
| Q36962841 | Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations |
| Q37616010 | Understanding of leukemic stem cells and their clinical implications. |
| Q47822802 | Using omics to explore complications of kidney transplantation. |
| Q47440281 | Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment |
Search more.